Condition: Obesity · Genetic Obesity · Sponsor: Rhythm Pharmaceuticals, Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway: * POMC or PCSK1 (Sub-study 035a) * LEPR (Sub-study 035b) * SRC1 (Sub-study 035c) * SH2B1 (Sub-study 035d) The objectives and endpoints are identical for these sub-studies.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital | Phoenix, Arizona, United States | — |
| HonorHealth Bariatric Center | Scottsdale, Arizona, United States | — |
| Children's Hospital Los Angeles | Los Angeles, California, United States | — |
| Children's Hospital Colorado | Aurora, Colorado, United States | — |
| Yale Center for Clinical Investigation | New Haven, Connecticut, United States | — |
| Advent Health | Altamonte Springs, Florida, United States | — |
| InQuest Medical Research | Suwanee, Georgia, United States | — |
| UMASS Memorial Medical Center | Worcester, Massachusetts, United States | — |
| University of Michigan | Ann Arbor, Michigan, United States | — |
| Metro Detroit Endocrinology Center | Dearborn, Michigan, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| St. Luke's Hospital | Chesterfield, Missouri, United States | — |
+ 44 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.